Angiotensin Peptides and SARS-CoV-2 Spike Binding

The study Naturally Occurring Angiotensin Peptides Enhance the SARS-CoV-2 Spike Protein Binding to Its Receptors by Oliveira and colleagues examines an unexpected connection between renin–angiotensin biology and viral receptor recognition. Rather than treating angiotensin peptides only as endocrine effectors, the authors test whether these short signaling molecules can directly influence the interaction of SARS-CoV-2 spike protein with host-cell receptors. The findings, published in the International Journal of Molecular Sciences in 2025, provide a biochemical basis for investigating angiotensin-peptide-dependent changes in viral attachment.

Study Background and Research Question

SARS-CoV-2 uses the spike glycoprotein to recognize host cells and initiate entry. The S1 subunit contains the receptor-binding region, whereas the S2 subunit contributes to membrane fusion after receptor engagement. ACE2 is the best-established host receptor, and neuropilin-1 (NRP1) can also support spike recognition. The reference study focuses additionally on AXL, a receptor that may contribute to infection in respiratory cells where ACE2 expression is relatively low. This receptor context is important because it broadens the biological settings in which spike binding may occur.

Angiotensin peptides are generated sequentially from angiotensinogen through the renin–angiotensin–aldosterone system. Angiotensin I is converted to angiotensin II, and angiotensin II can then be processed into shorter peptides. Angiotensin III is the (2–8) fragment of angiotensin II, with the sequence Arg-Val-Tyr-Ile-His-Pro-Phe. Its established physiological roles include regulation of vascular tone, renin release, and aldosterone production. In this context, Angiotensin III is an aldosterone secretion inducer, a pressor activity mediator, and an AT1 and AT2 receptor ligand. These properties have made it relevant as a cardiovascular research peptide, but they do not by themselves predict an effect on viral receptor binding.

The central question was therefore whether angiotensin peptides, including different chain lengths and sequence variants, alter the ability of SARS-CoV-2 spike protein to bind AXL, ACE2, or NRP1. The authors also asked whether activity depends on the peptide’s N-terminal or C-terminal residues and whether modifying tyrosine changes the interaction.

Key Innovation from the Reference Study

The main innovation is the systematic use of naturally occurring peptide fragments as molecular probes of spike–receptor binding. Instead of testing only angiotensin II, the investigators compare angiotensin I, angiotensin II, angiotensin III, angiotensin IV, shorter angiotensin (1–7)- and angiotensin (1–6)-related fragments, and selected sequence modifications. This design turns endogenous peptide processing into a structure–activity framework.

The distinction between terminal deletions is especially informative. C-terminal shortening of angiotensin II to angiotensin (1–7) or angiotensin (1–6) retained an enhancing effect similar to that of angiotensin II. By contrast, N-terminal deletion to angiotensin III or angiotensin IV produced more potent enhancement of spike–AXL binding. The study therefore suggests that the N-terminal region can restrain, rather than simply support, the activity of these peptides in this assay.

This conclusion is strengthened by the tyrosine experiments. Replacing tyrosine at position 4 with valine, or phosphorylating that tyrosine, increased spike–AXL binding. These observations point to chemical features around position 4 as possible determinants of activity. The paper does not establish a complete structural mechanism, but it identifies a tractable set of sequence and post-translational variables for future biophysical investigation.

Methods and Experimental Design Insights

The investigators used antibody-based binding assays to quantify interactions between spike protein and receptor proteins. The initial comparison examined spike binding to AXL, ACE2, and NRP1 in the presence of angiotensin II. Subsequent experiments tested a peptide panel organized by biological processing and sequence architecture. This included the longer angiotensin I (1–10), angiotensin II (1–8), C-terminally shortened products, N-terminally shortened products such as Angiotensin III (2–8) and angiotensin IV (3–8), and fragments derived from angiotensin (1–7).

This panel design provides several useful controls. Angiotensin I tests whether the longer precursor-like peptide is active. Angiotensin II serves as the principal endogenous comparator. Angiotensin (1–7) and angiotensin (1–6) distinguish the effect of C-terminal processing, while Angiotensin III and angiotensin IV test the consequences of removing one or more N-terminal residues. The substituted and phosphorylated peptides then probe whether activity is linked to side-chain identity or chemical modification rather than peptide length alone.

The study’s assay strategy is suitable for detecting changes in molecular association, but it should be interpreted as a binding assay rather than a direct infection model. A stronger signal indicates altered spike–receptor interaction under the experimental conditions; it does not by itself prove increased viral entry, replication, transmission, or disease severity. That distinction is central when translating the findings into respiratory-cell or animal studies.

Protocol Parameters

• Peptide comparison: Reproduce the reference study’s logic by testing angiotensin II alongside Angiotensin III, angiotensin IV, and selected C-terminally shortened fragments rather than evaluating a single peptide in isolation.
• Receptor panel: In the literature-backed design, assess spike binding to AXL and, where feasible, ACE2 and NRP1 so receptor-selective and broader effects can be separated.
• Sequence controls: Include matched truncation or substitution controls when examining the contribution of the N-terminal region or tyrosine chemistry. These are experimental design recommendations derived from the study’s comparisons, not universal concentration or incubation requirements.
• Follow-up validation: Treat antibody-based binding as an initial biochemical endpoint and add cell-surface binding, receptor-expression controls, pseudotyped entry, or infection-relevant assays before drawing conclusions about cellular susceptibility.

Core Findings and Why They Matter

Angiotensin II produced approximately a two-fold increase in spike–AXL binding, while it did not enhance spike binding to ACE2 or NRP1 in the reported assay. Angiotensin I, the longer precursor peptide, did not produce the same spike–AXL enhancement. These results indicate that the effect is not a general property of all angiotensin-system peptides and may depend on processing into shorter products. The quantitative findings are reported in the reference study.

C-terminal deletion generated angiotensin (1–7) and angiotensin (1–6) species with activity comparable to angiotensin II toward spike–AXL binding. The more striking result came from N-terminal deletion: Angiotensin III and angiotensin IV were more potent in the same assay, with angiotensin IV producing a reported 2.7-fold increase. Shorter products derived from angiotensin (1–7), including angiotensin (2–7) and angiotensin (5–7), also showed enhancement. Thus, peptide processing may alter spike-receptor binding in a direction that cannot be inferred solely from the canonical activity of the parent peptide.

Angiotensin IV also enhanced spike binding to ACE2 and NRP1, expanding the observation beyond AXL. The finding is important because it suggests that peptide-dependent modulation could be receptor-selective for some sequences but broader for others. It also places Angiotensin III in a useful comparative position: its established role as a renin–angiotensin–aldosterone system peptide can be studied alongside its experimentally observed effect on spike–AXL binding, without assuming that the two activities share an identical receptor mechanism.

Why this cross-domain matters, maturity, and limitations

The cardiovascular-to-antiviral bridge matters because angiotensin-peptide concentrations, processing, receptor signaling, and inflammatory physiology may change together during systemic disease. If endogenous fragments influence spike binding, local peptide metabolism could become relevant to how viral attachment is studied in different tissues. However, the evidence is currently biochemical and comparative. The reference study does not demonstrate that Angiotensin III or another peptide increases infection in human respiratory tissue, nor does it show that changing peptide levels alters clinical COVID-19 outcomes. The most defensible interpretation is that angiotensin peptides are candidate modulators of receptor binding and potential therapeutic targets for further testing.

Comparison with Existing Internal Articles

The internal article Angiotensin III: Translational Leverage in RAAS and Beyond emphasizes Angiotensin III as a mechanistic bridge between cardiovascular and neuroendocrine research. The 2025 reference study adds a distinct layer to that framework by testing peptide effects on a viral surface-protein interaction rather than focusing only on classical RAAS outputs. The two perspectives are complementary: one establishes why Angiotensin III is biologically informative, while the newer paper supplies sequence-resolved evidence for a possible role in SARS-CoV-2 receptor engagement.

A second related resource, Angiotensin III: Protocol Enhancements for RAAS and Viral Research, is useful for considering how RAAS peptide experiments might be organized across cardiovascular and viral workflows. The reference paper should remain the primary evidence base for the spike-binding claim, whereas internal protocol discussion should be treated as workflow context until independently validated in cell and infection systems.

Limitations and Transferability

Several limitations constrain direct translation. First, antibody-based binding assays can be influenced by protein immobilization, epitope accessibility, receptor folding, peptide stability, and assay matrix effects. They may not reproduce the geometry or avidity of spike engagement at a living cell membrane. Second, the reported receptor interactions do not establish whether the peptides bind spike, bind the receptor, change receptor conformation, or affect the presentation of an accessible epitope through another indirect process.

Third, the experiments do not define the concentration range, exposure duration, peptide metabolism, or compartmental distribution required for the observed effects in vivo. Angiotensin peptides are rapidly processed, and the abundance of Angiotensin III may differ substantially between plasma, tissue, and intracellular environments. Fourth, enhanced binding is not equivalent to productive entry. Cellular proteases, membrane organization, innate immune responses, and receptor abundance could strengthen, weaken, or reverse the effect in biological systems.

Transferability is therefore best approached in stages. Researchers can first reproduce the peptide-ranking pattern with purified proteins and orthogonal binding methods. They can then test receptor-expressing cells while monitoring receptor abundance and viability, followed by entry or infection models that distinguish attachment from downstream replication. These steps would clarify whether the sequence-dependent findings are robust and whether they are specific to a viral variant, receptor context, or peptide modification state.

Research Support Resources

For RAAS peptide comparison experiments, researchers can use Angiotensin III (human, mouse) (SKU A1043) to support workflows involving exogenous Angiotensin III exposure, receptor-signaling studies, or side-by-side testing of angiotensin fragments. Its documented sequence, analytical quality information, and handling guidance can help laboratories define reagent identity and storage conditions when extending the reference study’s binding observations into cardiovascular or viral research models.